GLP-1 Vision-Loss MDL Reaches 216 Cases as Mounjaro Claims Consolidate

What Happened

The federal litigation over GLP-1 drug-linked vision loss has reached a measurable milestone: 216 lawsuits were pending as of September 1, 2026 in a dedicated multidistrict litigation, MDL-3166, which consolidates claims that GLP-1 receptor agonists caused non-arteritic anterior ischemic optic neuropathy (NAION) — a sudden, usually irreversible loss of vision in one eye.

The docket, overseen by Chief Judge Richard Seeborg in California federal court, continues to grow, with Mounjaro (tirzepatide) users among the newest plaintiffs. Industry reports describe a filing in early September by a Louisiana man who says he lost sight in his right eye after using Mounjaro, naming Eli Lilly and a second GLP-1 manufacturer.

Who Is Affected

• Patients who used Mounjaro, Ozempic, Wegovy, Zepbound, Trulicity, or Saxenda and were later diagnosed with NAION.
• Eli Lilly and Novo Nordisk, both facing claims that their labels lacked adequate ocular warnings.
• Prescribers, who must weigh emerging ocular safety signals against established glycemic and weight-management benefits.
• Researchers handling incretin compounds, for whom adverse-event litigation is one proxy for a still-unresolved safety picture.

Timeline

• 2024–2025 — Lawsuits alleging GLP-1-associated NAION accumulate after published research links the drug class to the condition, and the Judicial Panel on Multidistrict Litigation consolidates the claims into MDL-3166 for coordinated pretrial proceedings.
• September 1, 2026 — The JPML's pending-docket report lists 216 actions in MDL-3166.
• September 2026 — New complaints continue to arrive, including the Louisiana Mounjaro filing; the separate gastrointestinal-injury litigation, MDL-3094, holds 4,022 cases before a different California judge.

What This Means for Researchers

Two consolidated dockets now track GLP-1 safety from different angles — 4,022 gastrointestinal-injury claims in MDL-3094 and 216 ocular claims in MDL-3166. For anyone working with semaglutide or tirzepatide material, the litigation is a reminder that the class's safety profile is still being written: post-marketing adverse-event data, not just efficacy trials, belong in any risk assessment. Consolidation also centralizes evidence gathering, so label-warning history and internal documents will surface through court filings rather than scattered reports.

How to Verify Your Peptides

• Our overview of how peptide testing works explains identity, purity, and endotoxin checks.
• For tirzepatide material, see the tirzepatide HPLC testing guide; for semaglutide, the semaglutide purity guide.
• A trusted third-party testing lab can independently confirm what you actually received.

Safe Alternatives

Litigation headlines tend to push some buyers toward unregulated copies — the opposite of a safety move. Research these compounds through our profiles for tirzepatide and semaglutide, and use the vendor directory to find suppliers that publish batch testing.

Sources

• Regulatory announcements (Judicial Panel on Multidistrict Litigation pending-docket report, September 2026)
• Industry reports (September 2026)